Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320203 | 0.72 | MGLL (0.40) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL8663722 | 0.71 | CPB2 (0.30) | — | |
| SCHEMBL21543843 | 0.68 | MGLL (0.34) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL16568461 | 0.65 | MGLL (0.38) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL3683381 | 0.65 | GSK3A (0.32) | MGLL | |
| SCHEMBL708908 | 0.63 | MGLL (0.38) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL28568487 | 0.63 | MGLL (0.38) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL11457779 | 0.61 | MGLL (0.42) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL9972351 | 0.61 | MGLL (0.42) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL28949204 | 0.61 | MGLL (0.35) | MGLLGMNNALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992005200-A1 | XENOBIOTIC-ANTIBODY CONJUGATES | CHEMEX PHARMACEUTICALS, INC. (US) | 1992-04-02 | — | — | WO | disclosed |